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HIV and malignancy
With the advent of highly active antiretroviral therapy (HAART), the complications associated with HIV infection have changed. The incidence of opportunistic infections has decreased and longevity of HIV-infected individuals has increased. However, malignancies are now the leading cause of mortality in the individual with HIV infection [1] . It has long been recognized that the incidence of B cell non-Hodgkin lymphoma (NHL) is increased in HIV-infected patients [2] . Moreover, the incidences of other non-AIDS-defining malignancies such as Hodgkin lymphoma have also increased in the HIV-positive population [3] . NHL and Hodgkin lymphoma in the setting of HIV infection tend to have an aggressive clinical presentation [4, 5] .
Prior to the widespread use of HAART, treatment for these malignancies followed the paradigm that patients could not tolerate intensive chemotherapy due to their underlying immunodeficiency. Randomized trials of standard doses of combination chemotherapy such as M-BACOD versus reduced doses showed inferior results for the standard dose arm due to increased hematologic toxicity and infections [6] . With the widespread use of antiretroviral therapy, however, it became possible to treat patients with more dose-intensive therapy [7] . As a consequence, the median survival for patients with HIV-associated lymphoma has improved [8] .
Stem cell transplantation
For patients with relapsed NHL, randomized trials have demonstrated that high-dose therapy with autologous stem cell transplantation (ASCT) is superior to standard-dose salvage therapy in the HIV-negative setting [9] . This approach has also been used in high-risk patients who are in first remission. Non-randomized trials of this highrisk group have demonstrated high rates of progressionfree survival (PFS) [10] . Similarly, trials of HIV-negative patients with Hodgkin lymphoma have shown that ASCT can provide long-term PFS for patients with relapsed disease [11] . As patients with HIV-associated lymphomas now have improved hematologic reserve due to antiretroviral therapy, the use of high-dose therapy with ASCT has been explored. This review will summarize these trials.
Lymphoma remains a leading cause of mortality in HIV-infected patients. In the HIVnegative setting, high-dose therapy with autologous stem cell transplantation has been a long accepted treatment for certain malignancies such as lymphoma and leukemia. Early transplant trials excluded older patients and patients with comorbidities such as HIV infection. The procedure-related mortality of transplantation, however, has decreased both due to the use of peripheral blood stem cells instead of bone marrow and due to the use of new reduced intensity conditioning regimens. During this same era, the treatment of HIV infection has also become more effective. Patients are no longer dying of opportunistic infections and in addition, their hematologic function has improved. With these advances in HIV therapy, it is possible for HIV-infected patients to mobilize an adequate number of stem cells for an autologous transplant. In addition, with appropriate antiretroviral therapy and infection prophylaxis, the HIV-infected patient can tolerate intensive doses of chemotherapy. This review will summarize clinical trials of autologous stem cell transplantation in HIV-positive patients. Furthermore, the field of solid-organ transplantation has grown to also include HIV-positive patients. The challenges in solid-organ transplantation are similar to allogeneic stem cell transplantation, namely that patients require chronic immunosuppression. This article will also review some of the approaches to allogeneic stem cell transplantation in the HIV-positive patient and provide a rationale for the broader use of stem cell transplantation for appropriate HIV-related hematologic malignancies. In addition, recent studies suggest that other hematologic malignancies such as acute myelogenous leukemia (AML) may have a higher incidence in the HIV-infected patient. A recent study suggests a two-fold increased risk of AML in HIV-infected patients than in the general HIV-negative population [12] . For HIV-negative patients with high-risk AML or relapsed AML, generally allogeneic transplantation is utilized rather than ASCT. Hence, the question now arises about the feasibility of allogeneic transplant in the HIV-infected patient with hematologic malignancies such as AML. The challenges of this approach as well as the results of recent series will be reviewed.
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Stem cell mobilization in HIV-positive patients
The first issue to be addressed in the autologous transplant patient, regardless of HIV status, is the potential for an adequate stem cell collection. Lymphoma patients have the challenge of prior exposure to myelosuppressive chemotherapy and radiotherapy. In addition, the HIVinfected patients also suffer from the effects of the HIV virus on the bone marrow and from the potentially myelosuppressive effects of certain antiretroviral therapies. The HIV virus is known to alter the bone marrow microenvironment and cytokine milieu [13] . However, it does not infect the primitive stem cells [14] . In addition, antiretroviral therapy can also have positive effects on the bone marrow as manifest by improved blood counts in HIV-positive patients on HAART without lymphoma [15] . In-vivo studies demonstrate an increase in marrow mononuclear cells and functional improvement in progenitor cell and stem cell assays with the addition of antiretrovirals [16] . Clinical studies have found an inverse relationship between the baseline CD4 þ cell count and mobilizable CD34 þ cell counts [17] . However, certain antiretrovirals such as azidothymidine (AZT) are known to be myelosuppressive and, therefore, their use is contraindicated in patients prior to stem cell mobilization. Other centers also follow this practice of avoiding AZT in preparation to stem cell collection [18] . Poor mobilization, however, remains a challenge. In our center, three out of 41 HIV-positive patients failed to mobilize after chemotherapy-based priming. One patient was subsequently collected with AMD 3100, a reversible inhibitor of chemokine stromal-derived factor I (SDF-I) binding to CXCR4. The downregulation of SDF-I binding results in rapid egress of hematopoietic stem cells from the marrow. In the other large reported series from Italy, five of the 16 patients enrolled were mobilization failures, three after second-line chemotherapy and two after cyclophosphamide [19] .
Another theoretical concern with stem cell collection is whether the use of GCSF could have deleterious effects on the HIV viral load. However, studies have shown that, in fact, G-CSF caused no significant changes in HIV viral load and demonstrated the clonogenic potential of CD34 þ Thy1 þ stem cells collected through apheresis from the HIV-infected patients. In the studies from City of Hope and from Italy, no increases in opportunistic infections or viral loads were seen during stem cell mobilization [20] .
Autologous stem cell transplantation
The initial reports of ASCT in HIV-infected patients were from France in the pre-HAART era [21] . A 40-yearold male with HIV-NHL, who was initially on zidovudine and zalcitabine for his HIV, underwent ASCT with BEAM (BCNU, etoposide, cytarabine, melphalan) conditioning for relapsed disease. Of note, the antiretroviral therapy was discontinued at the time of his NHL diagnosis and resumed only as monotherapy with lamivudine 5 months after ASCT. The patient engrafted, but his posttransplant course was complicated by cytomegalovirus (CMV) viremia, atypical mycobacterium pneumonia, and intestinal cryptosporidiosis. The authors concluded that high-dose therapy with ASCT was feasible in the HIV-infected patient but that until better HIV therapies were available, infection would remain a significant cause of morbidity.
With the widespread use of HAART in the mid-1990s, investigators again explored ASCT in HIV-positive patients. The initial series from France included 14 patients on HAART with relapsed or refractory NHL [22] . Attempts were made to maintain patients on HAART through stem cell collection and transplant and in fact 13 of the 14 were able to stay on HAART throughout. The series included a variety of histologies: six with Hodgkin lymphoma, three Burkitt's type NHL, two with immunoblastic NHL, one with lymphoblastic NHL, and one with primary effusion lymphoma. The conditioning regimens included high-dose chemotherapy alone in six patients and high-dose chemotherapy with total body irradiation in eight. Despite the use of HAART, opportunistic infections did occur. Two patients developed CMV viremia without any associated CMV disease. Of note, there were no statistically significant differences in the viral load before and after transplant for the group. Eight patients died, six from lymphoma, one from AIDS and one from a second tumor. However, the study was encouraging in that it set a platform that ASCT was feasible and with minimal infectious complications and deleterious effects on the HIV infection.
Other centers have also reported similar experiences. A larger trial from the City of Hope included 20 patients on HAART with either high-risk NHL in first remission or relapsed host disease or NHL [23] . Seventeen patients received a chemotherapy-based regimen of cyclophosphamide, BCNU, etoposide and three received a radiation-based regimen of 1200 cGY total body irradiation (TBI), cyclophosphamide, and etoposide. All patients engrafted, though one patient had a delayed engraftment of 23 days. This was ascribed to the use of AZT as part of his antiretroviral therapy. An attempt was made to continue HAART for all patients, but only nine were able to tolerate it throughout. The remainder resumed it at a median of 2 months after ASCT. The CD4 cell counts reach a nadir at 6 months after ASCT and recovered to pretransplant levels by 1 year. At the time of initial reporting with a median follow-up of nearly 32 months, progression-free survival was 85%. The series was recently updated to include 28 patients [24] . Median follow-up was 41 months and PFS was 78%. The incidence of opportunistic infections in this series was low and included PCP pneumonia in two patients not compliant with prophylaxis, CMV infection in three patients, and VZV in two. No patient died of an opportunistic infection.
The AIDS clinical trial group reported the results of a multicenter trial using a different preparative regimen. They used a regimen that had originally been designed for older patients in an attempt to reduce regimen-related toxicity (RRT) [25] . Twenty-seven patients were enrolled on the study, with ultimately 20 undergoing transplant. One patient died of venoocclusive disease. At day 100, 53% achieved a complete remission. Sixmonth event-free survival was 49.5%. The authors emphasized that seven patients did not receive a transplant due to disease progression and underscored the importance of patient selection, that is, chemotherapy responsive lymphoma and controlled HIV infection.
All the aforementioned studies confirmed the feasibility, tolerability, and efficacy of high-dose therapy and ASCT in HIV patients. In-vitro studies of immune reconstitution such as interleukin 7 levels, T cell subsets, and Tcell V-beta repertoires in a small number of HIV patients who underwent ASCT confirm the stability of immune reconstitution [26] .
Investigators have also attempted to assess whether the efficacy of the procedure is comparable to HIV-negative patients. An EBMT series of 40 HIV-positive patients compared them to 40 HIV-negative lymphoma patients matched for histology, age, disease status at ASCT, and year and country of ASCT. With a median follow-up of 36 months, the PFS for HIV-positive patients was not statistically different at 62% for HIV-positive patients and 69% for HIV-negative patients. The authors concluded that HIV status should not preclude patients from transplant, but that infectious complications should be monitored closely [27] .
Allogeneic transplantation
Solid-organ transplantation set the platform for allogeneic stem cell transplantation in that solid-organ transplant patients also need chronic immunosuppression. Hence, the issues of committing an already immunocompromised individual to further immunosuppression and the concerns of interactions between antiretrovirals and immunosuppressive medications are the same. The paradigm shift in solid-organ transplantation has occurred somewhat earlier than allogeneic stem cell transplantation. In fact, some organ transplant centers assert that the HIV patient should be considered no different than any other high-risk patient such as the older patient or patient with diabetes' [28 ] .
Immune recovery in allogeneic transplant
The literature on allogeneic transplantation in HIVpositive patients is much more sparse than that on ASCT. Data on allogeneic transplantation in patients with other disorders suggest that the rate of immune reconstitution after transplant is dependent on factors such as the type of conditioning regimen, HLA compatibility of the donor and host and the development of graft versus host disease (GVHD). In a transplant with an HIV-negative recipient, T lymphocyte recovery occurs by 30 days after transplant, though initially with predominantly CD8 þ cells [29] . Recovery of CD4 þ cells can take up to 6 months, as does recovery of normal T cell responses to mitogens [30] . Often, patients achieve a state of partial chimerism after transplant due to host-graft tolerance, not unlike that seen in solid organ allografting. Patients with non-HIVmediated immunodeficiency who achieve partial chimerism with allografting may recover adequate T-cell function. It is unknown whether the same degree of recovery would occur in the HIV-infected patient.
Early reports of allogeneic transplant were in the pre-HAART era. Investigators at Johns Hopkins reported on a 41-year-old male with HIV lymphoma, who received TBI cyclophosphamide conditioning followed by allogeneic bone marrow infusion. He received high-dose AZT before transplant and a lower dose after transplant [31] . There was no significant regimen-related toxicity. The patient engrafted at day 17, but ultimately died of lymphoma at day 47. At autopsy, no evidence of HIV either by culture or PCR was found in tissue specimens. This early experience underscored the feasibility of the procedure.
The EBMT published in abstract a retrospective review of 30 patients with varied hematologic malignancies who received an allograft between the years 1987 and 2003 [32 ] . A variety of conditioning and GVHD prophylaxis regimens were used. The overall incidence of grade II-IV GVHD was 9%. Treatment-related mortality (TRM) Stem cell transplantation in HIV-infected patients Krishnan 13 was 46% at 100 days and 68% at 2 years. Causes of death included pulmonary toxicity in eight patients, infection in four and HIV disease in two. There was a marked difference in survival in patients transplanted after 1996 (four out of eight surviving) versus two out of 22 before 1996. The authors ascribe this survival difference to the widespread use of HAART after 1996. Hence, this largest experience underscores the points that both reduction of TRM and control of the HIV infection are crucial to the success of allografting.
Reduced intensity conditioning
Alternate conditioning strategies that allow the establishment of an allogeneic graft without fully ablative conditioning may be a more attractive strategy in the HIV patient.
Studies in dogs have shown that using low-dose TBI with posttransplant immunosuppression can facilitate stable mixed chimerism after allografting [33] . This approach has been tried in humans. Initial studies were in older patients and those with organ dysfunction that would preclude intensive conditioning. The trial demonstrated that engraftment was possible as was clinical and molecular remissions of patients with poor risk hematologic malignancies [34] .
Therefore, the use of nonmyeloablative conditioning with its sufficient anti-leukemia and/or anti-lymphoma effects and reduced regimen-related toxicity might be the optimal approach in the HIV-positive patient with a hematologic malignancy. Investigators at the NCI explored this approach [35] . Two patients received a cyclophosphamide and fludarabine-based conditioning regimen. HAART was held 1 week prior to conditioning and resumed once the patients were maintaining adequate oral intake. Cyclosporin was used for GVHD prophylaxis. One patient developed grade II acute skin GVHD that was treated with prednisone. Despite the use of stronger immunosuppression, the HIV infection remained well controlled. One patient died of relapsed disease at 12 months and one remained in remission at 2 years of follow-up. Overall, the experience showed that the reduced intensity allografting is possible in the HIV-infected patient and that immunosuppression can be given with HAART. Clinical protocols are ongoing at the Fred Hutchinson Cancer Center and the City of Hope using different reduced-intensity conditioning regimens for HIV-positive patients with varied hematologic malignancies.
Conclusion
The role of ASCT has been well established in the HIVnegative setting for the treatment of relapsed or high-risk lymphoma. Multiple studies have now demonstrated that ASCT in a person with underlying HIV infection is feasible and has low RRT. The transplant approach to patients with HIV lymphoma at the City of Hope is to evaluate the lymphoma and to consider the HIV as a chronic condition akin to diabetes. We therefore consider patients with relapsed chemosensitive HIV-associated NHL or Hodgkin lymphoma as potential transplant candidates. In addition, select patients with NHL in first remission and high-risk features by the international prognostic index are also evaluated for ASCT. Similar to well controlled diabetes, well controlled HIV infection does not significantly increase the incidence of infections after ASCT if a program of adequate surveillance and prophylaxis is used. Future directions of study at the City of Hope are to use the platform of high-dose myeloablative therapy for gene therapy. Specifically, after high-dose chemotherapy, patients are 'rescued' with both unmodified stem cells as well as stem cells that have been transduced using a lentivirus vector containing three anti-HIV RNA elements (a short hairpin RNA targeted to tat/rev, a TAR-specific decoy sequence and a ribozyme targeted to CCR5) [24] . TAR or transcription activation response element is a hairpin-like structure at the beginning of the HIV transcript that binds TAT, a protein responsible for HIV RNA transcription. The TAR decoy sequence therefore binds and sequesters TAT from viral RNA thereby blocking HIV transcription. Two patients have been transplanted utilizing this strategy and results will be presented in the near future. Allogeneic stem cell transplantation in the HIV-positive patient is still in its infancy. Some of the theoretical concerns such as pharmacokinetic interactions between HAART and immunosuppressive medication and infection risk have, however, been allayed by the experience in solid-organ transplantation in HIV-positive patients. Approximately 40 000 new cases of HIV infection occur in the US annually. As these individuals age, their cancer risks will continue to rise. Therefore, broader application of therapies such as stem cell transplantation to the HIV-infected patient with a hematologic malignancy will continue to be of importance.
